Economic evaluation of gemcitabine plus cisplatin (GD) versus vinorelbine plus cisplatin plus Ifosfamide (NIP) in patients with locally advanced or metastatic non-small-cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 29s Year: 2003
Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001
Low dosage chemotherapy, with carboplatin (CBDCA) and vinorelbine (VNR), in advanced nonsmall cell lung cancer (NSCLC) in patients with low performance status Source: Eur Respir J 2003; 22: Suppl. 45, 528s Year: 2003
Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
A Phase II study of induction carboplatin (CBDCA) and docetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 162s Year: 2003
A phase 2 study of induction carboplatin (CBDCA) and dosetaxel (DOC) with concurrent radiation in early-stage non-small cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 375s Year: 2001
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Docetaxel (DOC) and gemcitabine (GEM) consist a safe and effective combination in the management of non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
First line treatment with gemcitabine plus cisplatine in non-small cell lung cancer: a comparison with etoposide plus cisplatin Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Different efficacy between carboplatin (Cpl) and gemcitabine (Gem) on median survival time of elderly non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Gemcitabine, ifosfamide and paclitaxel in patients with untreated advanced/metastatic nonsmall cell lung cancer (NSCLC) A phase II study Source: Eur Respir J 2003; 22: Suppl. 45, 28s Year: 2003
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
The comparison of paclitaxel-carboplatin (PCp) versus gemcitabine-cisplatin (GC) in the treatment of locally advanced or metastatic non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed (Pem) for advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Ifosfamide (IFO) is a valuable alternative to cisplatin (CDDP) for first-line chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC): A meta-analysis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013
A phase I trial of combined carboplatin and topotecan as 2nd line treatment in patients (pts) with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 30s Year: 2003
Gemcitabine and carboplatin (GC) versus mitomycin, ifosfamide and cisplatin (MIP): a phase III randomised comparison in stage IIIb or IV non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 399s Year: 2002
Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) versus gemcitabine (G) or paclitaxel (T) alone in elderly or unfit nonsmall cell lung cancer (NSCLC) patients. SICOG 9909 phase III trial Source: Eur Respir J 2003; 22: Suppl. 45, 527s Year: 2003
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006